Article Type
Review
Published
This article reviews the therapeutic landscape in myelofibrosis, which has
significantly improved, and emerging drugs with different
target pathways, alone or in combination with ruxolitinib.
promising.
Review
This article reviews the therapeutic landscape in myelofibrosis, which has
significantly improved, and emerging drugs with different
target pathways, alone or in combination with ruxolitinib.
promising.
Original Research
This article examines the relationship between U.S. Food and Drug Administration (FDA) approval and the publication of OS evidence to understand better the risks and benefits of delaying approval until OS evidence is available.